- Home
- AIRT vs MNOV Comparison
AIRT vs MNOV Comparison
Compare AIRT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRT | MNOV |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 72.7M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | AIRT | MNOV |
|---|---|---|
| Price | $20.87 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.7K | ★ 59.2K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $14.56 | $1.13 |
| 52 Week High | $26.70 | $1.96 |
Technical Indicators
Market Signals| Indicator | AIRT | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 38.86 |
| Support Level | $18.38 | $1.23 |
| Resistance Level | $20.97 | $1.62 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | -0.41 | -0.02 |
| Stochastic Oscillator | 15.30 | 18.42 |
Price Performance
Historical ComparisonAbout AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.